12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 March 2025
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
AI and novel technologies in lung function measurementStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 July 2016
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)Product type:GuidanceProgramme:NICE guidelinePublished: 27 November 2024
Asthma pathway (BTS, NICE, SIGN) (NG244)Product type:GuidanceProgramme:NICE guidelinePublished: 27 November 2024
Benralizumab for treating severe eosinophilic asthma (TA565)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 September 2019Published: 6 March 2019
Bronchial thermoplasty for severe asthma (IPG635)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 19 December 2018
Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital platforms to support self-management of asthma : early value assessmentStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating severe asthma with type 2 inflammation (TA751)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 December 2021
Mepolizumab for treating severe eosinophilic asthma (TA671)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 February 2021
MT684 Smart Peak Flow for monitoring asthmaStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Noninvasive Vagus Nerve Stimulation For reactive airway diseaseStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
OxyMask for delivering oxygen therapy (MIB160)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 September 2018
Reslizumab for treating severe eosinophilic asthma (TA479)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2017
Smartinhaler for asthma (MIB90)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 January 2017
Smart One for measuring lung function (MIB96)Product type:AdviceProgramme:Medtech innovation briefingPublished: 9 February 2017
Smart Peak Flow for monitoring asthma (MIB282)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 January 2022
Tezepelumab for treating severe asthma (TA880)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 April 2023
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 August 2014